Genzyme, which has major operations in MetroWest, has announced a collaboration with Cystic Fibrosis Foundation Therapeutics, a nonprofit organization, to research potential new drugs to treat the life-threatening condition.
The research will focus on the most common mutation CF patients face, named Delta F508. Genzyme, its parent company Sanofi, and the CF Foundation will collaborate to evaluate various compounds for corrections to the Delta F508.
According to the Cystic Fibrosis Foundation, the disease affects the lungs and digestive systems of an estimated 30,000 children and adults in the U.S. and 70,000 internationally.
